Adam's Take By Adam Feuerstein An FDA rejection derails Omeros, exposing the empty promises of its CEO
Adam's Take By Adam Feuerstein Northwest Bio marks ignominious anniversary of brain tumor study delay with silence
Adam's Take By Adam Feuerstein In new remarks, Cassava Sciences’ CEO shifts defense of embattled treatment for Alzheimer’s
Adam's Take By Adam Feuerstein The long wait for Cel-Sci to finally admit its cancer drug doesn’t work
Adam's Take By Adam Feuerstein CytoDyn’s wild weekend of data-mining study results ends in failure for its Covid treatment
Adam's Take By Adam Feuerstein Kulkarni victorious in best biopharma CEO vote; Leschly tops worst list
Adam's Take By Adam Feuerstein Why did this small biotech blow up? Because spinning bad drug data never works
Adam's Take By Adam Feuerstein CytoDyn CEO claims Covid-19 drug success while describing data suggesting study failure
Adam's Take By Adam Feuerstein Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer’s drug studies
Adam's Take By Adam Feuerstein Aurinia Pharma’s takeout hopes dim with new legal challenge to key drug patent
Adam's Take By Adam Feuerstein An FDA ruling on Cassava’s Alzheimer’s drug leaves bulls and bears waiting for more
Adam's Take By Adam Feuerstein Be careful who you sue: CytoDyn knowingly submitted an incomplete drug application to FDA, new documents show
Adam's Take By Adam Feuerstein Alzheimer’s scientists critique Cassava Sciences’ study results — overblown, inappropriate, uninterpretable
Adam's Take By Adam Feuerstein The failure of a cancer drug study leaves Cel-Sci on the brink of collapse
Adam's Take By Adam Feuerstein Cel-Sci CEO spoke privately with investors last week, raising doubts about long-delayed cancer drug
Adam's Take By Adam Feuerstein Fibrogen’s data manipulation scandal came with questions. There need to be answers
Adam's Take By Adam Feuerstein A ‘conditional’ EUA for a CytoDyn Covid treatment? FDA says no such thing exists
Adam's Take By Adam Feuerstein Who will Vertex buy? How much will it spend? Deal questions dominate its earnings call
Adam's Take By Adam Feuerstein Vertex, Amgen could be seeking new deals to fuel growth following pipeline stumbles
Adam's Take By Adam Feuerstein Failure has paid handsomely for Cassava Sciences’ CEO. His latest cash grab is a risky Alzheimer’s drug
Adam's Take By Adam Feuerstein Do surprise drug rejections signal a more conservative FDA? Don’t bet on it
Adam's Take By Adam Feuerstein Applied Therapeutics’ muted response to a clinical hold speaks volumes
Adam's Take By Adam Feuerstein CytoDyn is in financial and clinical distress, newly filed annual report shows
Adam's Take By Adam Feuerstein CytoDyn’s Covid-19 drug troubles escalate: Efficacy data are missing from study
Adam's Take By Adam Feuerstein Moderna’s skyrocketing market value is an indictment of the U.S. Covid-19 response
Adam's Take By Adam Feuerstein Applied Therapeutics amends investor deck, bolstering accusations made by anonymous critic
Adam's Take By Adam Feuerstein FDA refuses application for HIV drug from CytoDyn, raising more questions about its credibility
Adam's Take By Adam Feuerstein A moment of truth arrives for CytoDyn’s Covid-19 drug. Don’t let spin obscure it
Adam's Take By Adam Feuerstein ASCO 2020 takeaways: AstraZeneca does a star turn, KRAS fizzles, and cell therapy shows progress
Adam's Take By Adam Feuerstein Moderna carries a big-boy market valuation now, so it shouldn’t act like a biotech penny stock
Adam's Take By Adam Feuerstein With high hopes for its Covid-19 vaccine, Moderna stock value requires nearly mythical leap of faith
Adam's Take By Adam Feuerstein CytoDyn says lead HIV drug was not filed for FDA approval, as previously claimed